AbbVie, Big Pharma, Pharma M&A, BD&L, Corporate Venture Capital, Patent Cliff, Capital Allocation

AbbVie, Big Pharma, Pharma M&A, BD&L, Corporate Venture Capital, Patent Cliff, Capital Allocation

The $85 Billion shopping spree: How AbbVie bought, borrowed and built its way out of a Humira cliff

A complete strategic breakdown of AbbVie’s playbook on how it engineered its way out of the Humira patent cliff, analyzing M&A capital flows, pipeline risks, and therapeutic market positioning.